{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:05:13Z","timestamp":1763643913063,"version":"3.45.0"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Protecting individuals undergoing immunosuppressive therapy through vaccination remains a clinical challenge due to the heterogeneity of underlying conditions and immunosuppressive treatments. These patients are at increased risk of severe infections, yet vaccination uptake remains suboptimal. Although vaccine responses may be reduced, this review finds vaccination to be generally safe, except for live attenuated vaccines, which should be avoided due to the risk of severe disease. A structured, multidisciplinary approach to vaccination may enhance uptake and improve protection in this vulnerable patient group.<\/jats:p>","DOI":"10.61409\/v04250249","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:50:25Z","timestamp":1763556625000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Vaccination of individuals undergoing immunosuppressive therapy"],"prefix":"10.61409","author":[{"given":"Zitta Barrella","family":"Harboe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Henrik","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Asdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine","family":"Bertelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Bramow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik J\u00f8rn","family":"Ditzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Ekenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Helleberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Ulrik","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Julsgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten Schade","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Henrik Lawaetz","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Podlekareva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne Dam","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Troldborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Jensen-Fangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Bukan K, Pearce-Slade T, Eiberg M et al. Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic. Aging Clin Exp Res. 2023;35(5):917-23. https:\/\/doi.org\/10.1007\/s40520-023-02380-4","DOI":"10.1007\/s40520-023-02380-4"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Harboe ZB, Hald A, Ekenberg C et al. Implementation of a vaccination clinic for adult solid organ transplant candidates: a single-center experience. Vaccine. 2023;41(45):6637-44. https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.036","DOI":"10.1016\/j.vaccine.2023.09.036"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Davis JS, Ferreira D, Paige E et al. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020;33(3):e00035-19. https:\/\/doi.org\/10.1128\/CMR.00035-19","DOI":"10.1128\/CMR.00035-19"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Toruner M, Loftus Jr EV, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929-36. https:\/\/doi.org\/10.1053\/j.gastro.2008.01.012","DOI":"10.1053\/j.gastro.2008.01.012"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Roberts MB, Fishman JA. Immunosuppressive agents and infectious risk in transplantation: managing the \"net state of immunosuppression\". Clin Infect Dis. 2021;73(7):e1302-e1317. https:\/\/doi.org\/10.1093\/cid\/ciaa1189","DOI":"10.1093\/cid\/ciaa1189"},{"key":"ref5","unstructured":"Microcosm Publication of the American Society for Microbiology. Ins & outs of vaccines, fall 2020. https:\/\/asm.org\/ASM\/media\/Publication-Covers\/Microcosm\/Microcosm-2020-fall.pdf (09. sep 2025)"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Kucharzik T, Ellul P, Greuter T et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):879-913. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab052","DOI":"10.1093\/ecco-jcc\/jjab052"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Wang X, Patel C, Giles ML et al. Glucocorticoid dosing and implications for vaccination: evolution of global definitions. Clin Infect Dis. 2025;80(5):998-1004. https:\/\/doi.org\/10.1093\/cid\/ciae613","DOI":"10.1093\/cid\/ciae613"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Abhishek A, Peckham N, Pade C et al. Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open-label, superiority trial. Lancet Rheumatol 2024;6(2):e92-104. https:\/\/doi.org\/10.1016\/S2665-9913(23)00298-9","DOI":"10.1016\/S2665-9913(23)00298-9"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"L'huillier AG, Ferreira VH, Hirzel C et al. Cell-mediated immune responses after influenza vaccination of solid organ transplant recipients: secondary outcomes analyses of a randomized controlled trial. J Infect Dis. 2020;221(1):53-62. https:\/\/doi.org\/10.1093\/infdis\/jiz471","DOI":"10.1093\/infdis\/jiz471"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Svensson T, K\u00e4ttstr\u00f6m M, Hammarlund Y et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia: a randomized study by the Swedish CLL group. Vaccine. 2018;36(25):3701-3707. https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.012","DOI":"10.1016\/j.vaccine.2018.05.012"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Lagos LWA, de Abreu AJL, Caetano R, Braga JU. Yellow fever vaccine safety in immunocompromised individuals: a systematic review and meta-analysis. J Travel Med. 2023;30(2):taac095. https:\/\/doi.org\/10.1093\/jtm\/taac095","DOI":"10.1093\/jtm\/taac095"},{"key":"ref12","unstructured":"Centers for Disease Control and Prevention (CDC). Vaccines & immunizations: altered immunocompetence, 2024. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-best-practices\/altered-immunocompetence.html (09. sep 2025)"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Antinori A, Bausch-Jurken M. The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future. J Infect Dis. 2023;228(Suppl 1):S4-S12. https:\/\/doi.org\/10.1093\/infdis\/jiad181","DOI":"10.1093\/infdis\/jiad181"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ehmsen S, Asmussen A, Jeppesen SS et al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39(8):1034-1036. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.016","DOI":"10.1016\/j.ccell.2021.07.016"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Tsur SW, Zaher EA, Tsur M et al. Current immunological and clinical perspective on vaccinations in multiple sclerosis patients: are they safe after all? Int J Mol Sci. 2021;22(8):3859. https:\/\/doi.org\/10.3390\/ijms22083859","DOI":"10.3390\/ijms22083859"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Zullow S, Farraye FA. Updates on vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2019;13(3):229-239. https:\/\/doi.org\/10.1080\/17474124.2019.1565993","DOI":"10.1080\/17474124.2019.1565993"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Otero-Romero S, Lebrun-Fr\u00e9nay C, Reyes S et al. ECTRIMS\/EAN consensus on vaccination in people with multiple sclerosis: improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. 2023;29(8):904-925. https:\/\/doi.org\/10.1177\/13524585231168043","DOI":"10.1177\/13524585231168043"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Sherman AC, Tuan J, Cantos VD et al. COVID-19 vaccine efficacy in participants with weakened immune systems from 4 randomized controlled trials. Clin Infect Dis. 2024;79(2):364-374. https:\/\/doi.org\/10.1093\/cid\/ciae192","DOI":"10.1093\/cid\/ciae192"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Jena A, Mishra S, Deepak P et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2022;21(1):102927. https:\/\/doi.org\/10.1016\/j.autrev.2021.102927","DOI":"10.1016\/j.autrev.2021.102927"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Mwakingwe-Omari A, Lecrenier N, Naficy A et al. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: a review of clinical studies. Hum Vaccin Immunother. 2023;19(3):2278362. https:\/\/doi.org\/10.1080\/21645515.2023.2278362","DOI":"10.1080\/21645515.2023.2278362"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Ehmsen S, Asmussen A, Jeppesen SS et al. Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2022;40(8):800-801. https:\/\/doi.org\/10.1016\/j.ccell.2022.06.012","DOI":"10.1016\/j.ccell.2022.06.012"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Rubin LG, Levin MJ, Ljungman P et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100. https:\/\/doi.org\/10.1093\/cid\/cit684","DOI":"10.1093\/cid\/cit684"},{"key":"ref23","unstructured":"Sundhedsstyrelsen. Vaccination mod m\u00e6slinger, f\u00e5resyge og r\u00f8de hunde (MFR-vaccination) til voksne, 2025. https:\/\/www.sst.dk\/da\/Borger\/Vaccination-og-smitsomme-sygdomme\/Vaccination-af-voksne\/MFR-Vaccination (09. sep 2025)"},{"key":"ref24","unstructured":"Centers for Disease Control and Prevention (CDC). CDC Yellow Book 2026. Travelers with additional considerations: immunocompromised travelers. https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2024\/additional-considerations\/immunocompromised-travelers (10. okt 2025)"},{"key":"ref25","unstructured":"Sundhedsstyrelsen. Tilskud til vacciner til visse persongrupper, 2025. https:\/\/www.sst.dk\/da\/Fagperson\/Forebyggelse-og-tvaergaaende-indsatser\/Vaccination\/Vaccination-af-voksne\/Tilskud-til-vacciner (09. sep 2025)"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Martinson ML, Lapham J. Prevalence of immunosuppression among US adults. JAMA. 2024;331(10):880-882. https:\/\/doi.org\/10.1001\/jama.2023.28019","DOI":"10.1001\/jama.2023.28019"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Sormani MP, De Rossi N, Schiavetti I et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780-789. https:\/\/doi.org\/10.1002\/ana.26028","DOI":"10.1002\/ana.26028"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Euchi HLE, Chirpaz E, Foucher A et al. Vaccination against influenza and pneumococcal infections in patients with autoimmune disorders under biological therapy: coverage and attitudes in patients and physicians. Eur J Intern Med. 2019;69:25-31. https:\/\/doi.org\/10.1016\/j.ejim.2019.08.010","DOI":"10.1016\/j.ejim.2019.08.010"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Johansen ND, Vaduganathan M, Bhatt AS et al. Electronic nudges to increase influenza vaccination in patients with chronic diseases: a randomized clinical trial. JAMA. 2024;332(22):1900-1911. https:\/\/doi.org\/10.1001\/jama.2024.21060","DOI":"10.1001\/jama.2024.21060"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:51:45Z","timestamp":1763643105000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V04250249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v04250249","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}